Decision: Favourable
Study Title:
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
NREC Code:
22-NREC-CT-010
Decision:
Favourable
Meeting Date:
26/01/2022
Study Type:
CT application
Principal Investigator:
Professor Ray McDermott
Sponsor:
MSD